BNP Paribas Asset Management’s CytomX Therapeutics CTMX Stock Holding History

BNP Paribas Asset Management’s Portfolio CTMX Stock Details CTMX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$10.2K	Buy	+2,727	New	+$10.4K	﹤0.01%	2223

Other funds holding CTMX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

BNP Paribas Asset Management's CTMX Position: Q2 2026 in Review

BNP Paribas Asset Management opened a new position in CytomX Therapeutics (CTMX) in Q2 2026: 2,727 shares worth $10.2K. The stake represents ﹤0.01% of the portfolio and ranks #2223 among its holdings.

179 funds tracked by Wall St. Rank hold CTMX as of Q2 2026.

BNP Paribas Asset Management held 2,727 shares of CytomX Therapeutics worth $10.2K as of Q2 2026.
CytomX Therapeutics was a new BNP Paribas Asset Management position in Q2 2026.
CytomX Therapeutics made up ﹤0.01% of BNP Paribas Asset Management's portfolio in Q2 2026, its #2223 holding.
179 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q2 2026.

Based on BNP Paribas Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.